Literature DB >> 20639215

Secreted PLA2 induces proliferation in astrocytoma through the EGF receptor: another inflammation-cancer link.

Marita Hernández1, Rubén Martín, Miriam Daniela García-Cubillas, Patricia Maeso-Hernández, María Luisa Nieto.   

Abstract

We have investigated mechanisms that contribute to reinforce the relationship between inflammation and cancer. Secreted phospholipase A(2) group IIA (sPLA(2)-IIA) is a molecule relevant in inflammatory events and has been proposed as a marker for some of these. Previously, we reported the mitogenic properties of this sPLA(2) in the human astrocytoma cell line 1321N1. Here, we go deeper into the mechanisms that link this inflammatory protein with proliferation in one of the most aggressive types of tumors. We found that phosphorylation of the extracellular regulated kinase (ERK) was preceded by the activation of the small GTPase Ras, and both failed to be activated by inhibiting protein kinase C (PKC). Fractionation and immunofluorescence studies revealed translocation of PKC alpha, delta, and epsilon to the membrane fraction upon stimulation with sPLA(2)-IIA. Immunoprecipitation analysis showed that sPLA(2)-IIA induces phosphorylation of the epidermal growth factor receptor (EGFR) through a PKC-dependent pathway. We found that phosphorylation of this receptor contributed to Ras and ERK activation and that inhibition of ERK, PKC, and EGFR blocked the mitogenic response induced by sPLA(2)-IIA. This study showed that sPLA(2)-IIA is able to bring into play EGFR to trigger its signaling and that PKC leads the distribution of resources. Interestingly, we found that this is not a cell-specific response, because sPLA(2)-IIA was also able to transactivate EGFR in MCF7 human breast cancer cells. Therefore, this mechanism could contribute to worsen the prognosis of a tumor in an inflammatory microenvironment. We also present more links of the tumor chain possibly susceptible to targeting.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20639215      PMCID: PMC3018927          DOI: 10.1093/neuonc/noq078

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  56 in total

Review 1.  Increasing molecular diversity of secreted phospholipases A(2) and their receptors and binding proteins.

Authors:  E Valentin; G Lambeau
Journal:  Biochim Biophys Acta       Date:  2000-10-31

2.  Human group IIA secretory phospholipase A2 induces neuronal cell death via apoptosis.

Authors:  Tatsurou Yagami; Keiichi Ueda; Kenji Asakura; Satoshi Hata; Takayuki Kuroda; Toshiyuki Sakaeda; Nobuo Takasu; Kazushige Tanaka; Takefumi Gemba; Yozo Hori
Journal:  Mol Pharmacol       Date:  2002-01       Impact factor: 4.436

3.  Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade.

Authors:  J R Graff; B W Konicek; J A Deddens; M Chedid; B M Hurst; B Colligan; B L Neubauer; H W Carter; J H Carter
Journal:  Clin Cancer Res       Date:  2001-12       Impact factor: 12.531

Review 4.  EGFR and cancer prognosis.

Authors:  R I Nicholson; J M Gee; M E Harper
Journal:  Eur J Cancer       Date:  2001-09       Impact factor: 9.162

5.  Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients.

Authors:  M L Simmons; K R Lamborn; M Takahashi; P Chen; M A Israel; M S Berger; T Godfrey; J Nigro; M Prados; S Chang; F G Barker; K Aldape
Journal:  Cancer Res       Date:  2001-02-01       Impact factor: 12.701

Review 6.  Phospholipase A(2) in vascular disease.

Authors:  E Hurt-Camejo; G Camejo; H Peilot; K Oörni; P Kovanen
Journal:  Circ Res       Date:  2001-08-17       Impact factor: 17.367

7.  Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules.

Authors:  H R Ashar; L James; K Gray; D Carr; S Black; L Armstrong; W R Bishop; P Kirschmeier
Journal:  J Biol Chem       Date:  2000-09-29       Impact factor: 5.157

Review 8.  Roles of secretory phospholipases A(2) in inflammatory diseases and trauma.

Authors:  T J Nevalainen; M M Haapamäki; J M Grönroos
Journal:  Biochim Biophys Acta       Date:  2000-10-31

9.  Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris.

Authors:  K Kugiyama; Y Ota; S Sugiyama; H Kawano; H Doi; H Soejima; S Miyamoto; H Ogawa; K Takazoe; H Yasue
Journal:  Am J Cardiol       Date:  2000-10-01       Impact factor: 2.778

10.  Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cells.

Authors:  Edward Im; Friederike C von Lintig; Jeffrey Chen; Shunhui Zhuang; Wansong Qui; Shoaib Chowdhury; Paul F Worley; Gerry R Boss; Renate B Pilz
Journal:  Oncogene       Date:  2002-09-12       Impact factor: 9.867

View more
  19 in total

1.  Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition-mediated cell death in K-ras mutant lung cancer cells.

Authors:  Jessica A Yu; Howard Li; Xianzhong Meng; David A Fullerton; Raphael A Nemenoff; John D Mitchell; Michael J Weyant
Journal:  J Thorac Cardiovasc Surg       Date:  2012-09-29       Impact factor: 5.209

2.  Plasma phospholipase A2 activity may serve as a novel diagnostic biomarker for the diagnosis of breast cancer.

Authors:  Jingkun Qu; Xixi Zhao; Jizhao Wang; Chao Liu; Yuchen Sun; Hui Cai; Jianlin Liu
Journal:  Oncol Lett       Date:  2018-01-31       Impact factor: 2.967

3.  Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo.

Authors:  Jessica A Yu; David Mauchley; Howard Li; Xianzhong Meng; Raphael A Nemenoff; David A Fullerton; Michael J Weyant
Journal:  J Thorac Cardiovasc Surg       Date:  2012-11       Impact factor: 5.209

4.  Serum amyloid A, phospholipase A₂-IIA and C-reactive protein as inflammatory biomarkers for prostate diseases.

Authors:  Mario Menschikowski; Albert Hagelgans; Susanne Fuessel; Olga A Mareninova; Liana Asatryan; Manfred P Wirth; Gabriele Siegert
Journal:  Inflamm Res       Date:  2013-09-24       Impact factor: 4.575

5.  Secreted phospholipase A2-IIA-induced a phenotype of activated microglia in BV-2 cells requires epidermal growth factor receptor transactivation and proHB-EGF shedding.

Authors:  Rubén Martín; Claudia Cordova; Maria L Nieto
Journal:  J Neuroinflammation       Date:  2012-07-02       Impact factor: 8.322

Review 6.  Factors influencing the eicosanoids synthesis in vivo.

Authors:  Jarosław Szefel; Wiesław Janusz Kruszewski; Ewa Sobczak
Journal:  Biomed Res Int       Date:  2015-03-11       Impact factor: 3.411

Review 7.  Examination of Epigenetic and other Molecular Factors Associated with mda-9/Syntenin Dysregulation in Cancer Through Integrated Analyses of Public Genomic Datasets.

Authors:  Manny D Bacolod; Swadesh K Das; Upneet K Sokhi; Steven Bradley; David A Fenstermacher; Maurizio Pellecchia; Luni Emdad; Devanand Sarkar; Paul B Fisher
Journal:  Adv Cancer Res       Date:  2015-05-23       Impact factor: 6.242

8.  The carcinogenic liver fluke, Clonorchis sinensis: new assembly, reannotation and analysis of the genome and characterization of tissue transcriptomes.

Authors:  Yan Huang; Wenjun Chen; Xiaoyun Wang; Hailiang Liu; Yangyi Chen; Lei Guo; Fang Luo; Jiufeng Sun; Qiang Mao; Pei Liang; Zhizhi Xie; Chenhui Zhou; Yanli Tian; Xiaoli Lv; Lisi Huang; Juanjuan Zhou; Yue Hu; Ran Li; Fan Zhang; Huali Lei; Wenfang Li; Xuchu Hu; Chi Liang; Jin Xu; Xuerong Li; Xinbing Yu
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

9.  Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells.

Authors:  Zhongyun Dong; Jaroslaw Meller; Paul Succop; Jiang Wang; Kathryn Wikenheiser-Brokamp; Sandra Starnes; Shan Lu
Journal:  Int J Oncol       Date:  2014-06-10       Impact factor: 5.650

10.  Prognostic value of systemic immune-inflammation index in patients with gastric cancer.

Authors:  Kang Wang; Feiyu Diao; Zhijun Ye; Xinhua Zhang; Ertao Zhai; Hui Ren; Tong Li; Hui Wu; Yulong He; Shirong Cai; Jianhui Chen
Journal:  Chin J Cancer       Date:  2017-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.